Several therapeutic approaches are now being explored to overcome resistance, and, for example, initial results of targeting both CD19 and CD22 in ALL or combining ibrutinib and CAR T19 [20] are showing promising results. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.